If you liked this article you might like

Alexion Rises More Than 5% After Beating Consensus
Acorda Shares Fall 5% in an Earnings Miss
Biomarin Newly Approved Drug for Rare, Childhood Disease Will Cost $700K Per Year
Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports